Skip to main content

Table 2 Median pharmacokinetic parameters after intramuscular injections of paliperidone palmitate (150 mg eq.)

From: A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

  2nd injection 8th injection 14th injection
PK parameter N Median
(min-max)
N Median
(min-max)
N Median
(min-max)
Cpredose, ng/mL 200 21.3
(0.46-81.2)
119 28.4
(6.03-92.6)
105 39.9
(9.17-134)
Cmin, ng/mL 189 17.0
(0.46-46.7)
114 27.0
(6.03-92.6)
105 35.1
(9.17-120)
Cmax, ng/mL 189 50.5
(11.5-232)
114 50.5
(10.7-172)
105 56.5
(17.6-172)
tmax, daysa 189 7.96
(0.00-28.02)
114 8.48
(0.00-30.95)
105 7.00
(0.00-30.00)
AUCtau, h*ng/mL 183 23325
(3652-86457)
111 26831
(6335-87393)
105 31970
(9244-96840)
Cavg, ng/mL 183 34.7
(5.44-129)
114 40.0
(9.42-130)
105 47.8
(13.8-144)
FI, % 183 92.7
(39.8-215)
114 55.0
(15.6-179)
105 41.2
(5.83-111)
  1. atmax was calculated in hours and recalculated to days here. FI = fluctuation index